Global HER2 Assay Kit Market Strategic Research Report

Scope of the Report

The global HER2 Assay Kit market size is predicted to grow from US$ 72.78 million in 2025 to US$ 111 million in 2032; it is expected to grow at a CAGR of 6.2% from 2026 to 2032.

HER2 testing kits primarily determine HER2 status by detecting the overexpression of HER2 protein or the amplification of the HER2 gene within tumor tissue. Specifically, the IHC (Immunohistochemistry) method utilizes anti-HER2 antibodies to bind with HER2 proteins in tissue sections; following a chromogenic visualization process, results are categorized as 0, 1+, 2+, or 3+ based on staining intensity. Conversely, ISH/FISH (In Situ Hybridization/Fluorescence In Situ Hybridization) methods employ HER2 gene probes—alongside reference probes such as CEP17—to perform hybridization, assessing gene amplification status based on signal counts and ratios. These products are primarily utilized in the pathological classification, prognostic assessment, and companion diagnostics for breast cancer, gastric cancer, and gastroesophageal junction cancer. Their objective is to assist in identifying patients suitable for HER2-targeted therapies, such as trastuzumab, pertuzumab, and trastuzumab deruxtecan.

The upstream supply chain encompasses fluorescent/chromogenic probes, buffers, enzymatic reagents, microscope slides, quality control materials, anti-fading agents, and pathological testing equipment; the downstream market targets hospital pathology departments, third-party laboratories, and oncology centers.Globally, the average unit price for HER2 testing kits stands at approximately $80 per kit, with global sales reaching approximately 930,000 kits. The industry boasts an annual production capacity of 1.5 million to 2 million kits and maintains a profit margin of approximately 50%.

The global market for human HER2 gene amplification testing kits is poised for growth, driven by advancements in precision medicine, companion diagnostics, and the expanding scope of HER2-targeted therapies. Consequently, market demand is continuously trending toward greater standardization, automation, and high sensitivity. As the demand for HER2 testing rises across breast cancer, gastric cancer, and various other cancer types, technologies such as FISH, CISH, and Dual ISH will increasingly prioritize interpretive consistency, testing efficiency, and compatibility with automated pathology platforms. Future market competition will center on probe stability, result accuracy, reagent compatibility, regulatory compliance, and endorsement by clinical guidelines; concurrently, emerging therapeutic stratification concepts—such as "HER2-low" and "HER2-ultralow"—are expected to drive further refinement and segmentation of clinical testing scenarios.

Key Questions Addressed in this Report

What is the 10-year outlook for the global HER2 Assay Kit market?

What factors are driving HER2 Assay Kit market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do HER2 Assay Kit market opportunities vary by end market size?

How does HER2 Assay Kit break out by Type, by Application?

This report presents a comprehensive overview of the global HER2 Assay Kit market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Fluorescence In Situ Hybridization Kit
• Chromogenic In Situ Hybridization Kit

Segment by Probe Type

• HER-2 Single-Color Probe Kit
• HER-2 Dual-Color Probe Kit
• HER-2/CEP17 Dual-Probe Kit
• HER-2 Locus-Specific Probe Kit
• HER-2 Copy Number Probe Kit

Segment by Fluorescent Signal

• Single-Color FISH Kit
• Dual-Color FISH Kit
• Multi-Color FISH Kit

Segment by Application

• Hospital
• Clinic
• Laboratory
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global HER2 Assay Kit market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic, Laboratory evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact